Avelumab and other recent advances in Merkel cell carcinoma.

Bommareddy, Praveen K; Kaufman, Howard L

Bommareddy, Praveen K; Kaufman, Howard L.

Affiliation

Bommareddy PK; Departments of Surgery & Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.
Kaufman HL; Departments of Surgery & Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.

Future Oncol ; 13(30): 2771-2783, 2017 Dec.

Article in En | MEDLINE | ID: mdl-28976209

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents, Immunological/therapeutic use; Carcinoma, Merkel Cell/drug therapy; Molecular Targeted Therapy; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological/pharmacology; B7-H1 Antigen/antagonists & inhibitors; Biomarkers, Tumor/antagonists & inhibitors; Carcinoma, Merkel Cell/diagnosis; Carcinoma, Merkel Cell/etiology; Carcinoma, Merkel Cell/mortality; Humans; Incidence; Merkel cell polyomavirus; Neoplasm Metastasis; Neoplasm Staging; Polyomavirus Infections/complications; Symptom Assessment; Treatment Outcome; Tumor Escape

Key words

Merkel cell carcinoma; avelumab; immunotherapy; pembrolizumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Merkel Cell / Molecular Targeted Therapy / Antineoplastic Agents, Immunological / Antibodies, Monoclonal Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies Limits: Humans Language: En Journal: Future Oncol Year: 2017 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google